Retail pharmacy sales on the rise
The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.
The market for retail pharmacy sales rose 15.8% during the second quarter, according to Newton, PA-based Scott-Levin. In its "Source Prescription Audit," the company reported that pharmaceutical companies generated a total of $20.7 billion during the quarter.
Driven by the success of Imitrex, Flonase, Epivir and Serevent, Glaxo Wellcome was responsible for the largest portion (6.7%) of retail pharmacy sales. Merck added the second largest share (6.5%) with Aocor, Fosamax, Cozaar and Hyzaar. Pfizer contributed the third largest sales (6.2%) with strong performances by Norvasc, Cardura, Zithromax and Zyrtec.
American Home Products and Bristol-Myers Squibb rounded out the top five in second-quarter sales with 6% and 5.7%, respectively.
Four of the top 10 corporations increased their U.S. retail pharmacy dollars by more than 20%: Eli Lilly and SmithKline Beecham raised their revenues by 21%; Bristol-Myers Squibb improved its stance by 24%; and Schering-Plough boosted its sales by 32%. PR
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
